Nifedipine sustained-release capsules

Nifedipine is a dihydropyridine calcium antagonist that selectively inhibits the transmembrane transport of calcium ions into myocardial cells and smooth muscle cells, and inhibits the release of calcium ions from intracellular pools without changing the plasma calcium ion concentration. Pharmacological action: This product can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase the delivery of myocardial oxygen in patients with coronary artery spasm, and relieve and prevent coronary artery spasm. It can also inhibit myocardial contraction, reduce myocardial metabolism, and reduce myocardial oxygen consumption. On the other hand, it can relax peripheral resistance vessels, reduce peripheral resistance, reduce systolic and diastolic blood pressure, and reduce cardiac afterload. This product can delay the sinoatrial node function and atrioventricular conduction of isolated hearts; electrophysiological studies of whole animals and humans have not found that this product has the effect of delaying atrioventricular conduction, prolonging the recovery time of the sinoatrial node, and slowing down the sinoatrial node rate. Toxicological action: Carcinogenicity, mutagenicity and reproductive toxicity have no carcinogenic effect. No mutagenicity. Large doses can reduce the fertility of female mice, cause teratogenesis, and induce abortion (increased drug absorption rate in fetal mice, increased fetal mortality, and decreased survival rate of newborn mice). Pregnant monkeys taking 2/3-2 times the maximum human dose can cause small placenta and chorionic dysplasia; giving rats 3 times the maximum human dose can cause prolonged pregnancy.

The main ingredient of this product is nifedipine, its chemical name is: 2,6-dimethyl-4 (2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylic acid dimethyl ester. Its structural formula is: Molecular formula: C17H18N2O6 Molecular weight: 346.34

This product is a capsule, and the contents are brown particles.

1. Hypertension (alone or in combination with other antihypertensive drugs). 2. Angina pectoris: especially variant angina pectoris.

1 Swallow the whole tablet on an empty stomach. Do not chew or break it apart before taking. 2 Start with a small dose. The initial dose is 20 mg/time, and the maximum dose is 60 mg/time, once a day. The maximum daily dose does not exceed 120 mg. 3 The dose of nifedipine should be gradually adjusted depending on the patient's tolerance and control of angina pectoris. The patient's blood pressure needs to be monitored before increasing the dose. If the patient's symptoms are obvious, the dose adjustment period can be shortened according to the patient's response to the drug. 4 No "rebound" symptoms were observed when the drug was discontinued, but the dose still needs to be gradually reduced and the patient's condition should be closely observed. 5 The dose of ordinary preparations can be safely replaced with the dose of sustained-release preparations. For example: 30 mg/time of ordinary preparations, three times a day, can be replaced with 90 mg/time of sustained-release preparations, once a day.

1 Common adverse reactions include peripheral edema (proportional to the dose); headache, etc. 2 Adverse reactions with uncertain relationship to this product: dizziness; nausea; constipation; fatigue; facial flushing and heat sensation. 31%-3% adverse reactions: chest pain; leg pain; paresthesia; vertigo; rash; leg cramps; nosebleeds; rhinitis; impotence; frequent urination, etc. 41% adverse reactions: cellulitis; chills; facial edema; neck pain; pelvic pain; atrial fibrillation; bradycardia; cardiac arrest; premature beats; hypotension; palpitations; phlebitis; postural hypotension; tachycardia; anxiety; loss of libido; depression; insomnia; drowsiness; pruritus; night sweats; abdominal pain; diarrhea; dry mouth; indigestion; esophagitis; bloating; gastrointestinal bleeding; vomiting; lymphadenopathy; gout; weight loss; joint pain; joint

It is contraindicated in patients allergic to nifedipine.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Contraindicated for pregnant and lactating women. Precautions for the elderly: Elderly people generally tolerate nifedipine well, but treatment should be cautious.

1 Common adverse reactions include peripheral edema (proportional to the dose); headache, etc. 2 Adverse reactions with uncertain relationship to this product: dizziness; nausea; constipation; fatigue; facial flushing and heat sensation. 31%-3% adverse reactions: chest pain; leg pain; paresthesia; vertigo; rash; leg cramps; epistaxis; rhinitis; impotence; frequent urination, etc. 41% adverse reactions: cellulitis; chills; facial edema; neck pain; pelvic pain; atrial fibrillation; bradycardia; cardiac arrest; premature beats; hypotension; palpitations; phlebitis; postural hypotension; tachycardia; anxiety; loss of libido; depression; insomnia; lethargy; pruritus; night sweats; abdominal pain; diarrhea; dry mouth; indigestion; esophagitis; bloating; gastrointestinal bleeding; vomiting; lymphadenopathy; gout; weight loss; arthralgia; arthritis; myalgia; dyspnea; cough; pharyngitis; blurred vision; amblyopia; conjunctivitis; diplopia; kidney stones, etc. 5 Rare adverse reactions: allergic hepatitis; alopecia; anemia; antinuclear antibody positive arthritis; erythromelalgia; exfoliation. 6 Exfoliative dermatitis; fever; gingival hyperplasia; male breast development; leukopenia; mood swings; muscle pain; nervousness; purpura; tremor; sleep disorders; Stevens-Johnson syndrome; syncope; thrombocytopenia; toxic epidermal fusion necrosis; instant blindness at peak blood drug concentration; tremor; urticaria, etc.

Keep in a light-proof and airtight container.

20mg

24 months

Harbin Pharmaceutical Group Co., Ltd. GENERAL Pharm. FACTORY

• Founded in:

  1994-05-19

• Address:

  No. 388, Hahei Highway, Hulan District (production base No. 109, Xuefu Road, Nangang District, No. 1, Junmin Street, Xiangfang District)

• Tax NO.:

  912301008280277137

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view